Login to Your Account

Diabetes ‘Foresite’ pumps Intarcia $200M for exenatide delivery already in phase III

By Randy Osborne
Staff Writer

Tuesday, April 1, 2014

With its once-yearly implanted-pump exenatide in phase III FREEDOM trials for type 2 diabetes, Intarcia Therapeutics Inc. became the highest-valued privately held biotech in the history of the industry by way of a $200 million financing that includes $57 million from the Foresite Capital Fund II, a growth equity stash designed to back firms “when we know things are working,” said managing director Christine Aylward.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription